Cadrenal Therapeutics (CVKD)

• Market cap: $16.4M
• 1 day: -5.02%
• 5 days: -20%
• 1 month: -7.16%
• 3 months: -47.01%
• 6 months: -35.13%
• Year to date: -4.5%
• 1 year: -59.77%
• 5 years: -88.67%
• 10 years: -88.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Employees: 4